Pub Date : 2024-11-12eCollection Date: 2024-10-01DOI: 10.1183/20734735.0235-2023
Yizhong Zheng, Jian Eu Tai, Brendon J Yee
Central sleep apnoea (CSA) is characterised by recurrent episodes of airway cessation or reduction in the absence of respiratory effort. Although CSA is less common than obstructive sleep apnoea, it shares similar symptoms. CSA can be secondary to various medical conditions, high altitude and medication exposure. CSA can also emerge during obstructive sleep apnoea therapy. There are a range of treatment options and selecting the right therapy requires an understanding of the pathophysiology of CSA. This review explores the aetiology, pathophysiology and clinical management of non-hypercapnic CSA.
{"title":"Management of central sleep apnoea: a review of non-hypercapnic causes.","authors":"Yizhong Zheng, Jian Eu Tai, Brendon J Yee","doi":"10.1183/20734735.0235-2023","DOIUrl":"https://doi.org/10.1183/20734735.0235-2023","url":null,"abstract":"<p><p>Central sleep apnoea (CSA) is characterised by recurrent episodes of airway cessation or reduction in the absence of respiratory effort. Although CSA is less common than obstructive sleep apnoea, it shares similar symptoms. CSA can be secondary to various medical conditions, high altitude and medication exposure. CSA can also emerge during obstructive sleep apnoea therapy. There are a range of treatment options and selecting the right therapy requires an understanding of the pathophysiology of CSA. This review explores the aetiology, pathophysiology and clinical management of non-hypercapnic CSA.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"230235"},"PeriodicalIF":2.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555585/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-12eCollection Date: 2024-10-01DOI: 10.1183/20734735.0034-2024
Beenish Iqbal, Eihab Bedawi, Najib M Rahman
Malignant pleural effusions (MPE) tend to recur and require definitive treatment with either chest drain and talc pleurodesis or indwelling pleural catheters (IPCs), which offer similar symptomatic benefits. In recent years, IPCs have become popular due to the presumed convenience of an outpatient procedure followed by home drainage leading to a misconception of IPCs being an ideal treatment for MPE. However, IPCs predispose the patient to multiple complications and have significant physical and psychological implications that are under-recognised. Patients require additional clinical reviews, hospital admissions and treatment for these complications related to IPCs. Additionally, there is a huge psychological impact of living with a home catheter that is a constant reminder of their cancer and this has been shown to affect quality of life negatively. Hence, IPCs should not be considered the "ideal" treatment for MPE management and clinicians should reflect the equipoise of the evidence for the benefits and accurately reflect the adverse effects of IPCs in their discussions with patients to facilitate informed decision making.
{"title":"Pro: indwelling pleural catheters cause harm to patients.","authors":"Beenish Iqbal, Eihab Bedawi, Najib M Rahman","doi":"10.1183/20734735.0034-2024","DOIUrl":"https://doi.org/10.1183/20734735.0034-2024","url":null,"abstract":"<p><p>Malignant pleural effusions (MPE) tend to recur and require definitive treatment with either chest drain and talc pleurodesis or indwelling pleural catheters (IPCs), which offer similar symptomatic benefits. In recent years, IPCs have become popular due to the presumed convenience of an outpatient procedure followed by home drainage leading to a misconception of IPCs being an ideal treatment for MPE. However, IPCs predispose the patient to multiple complications and have significant physical and psychological implications that are under-recognised. Patients require additional clinical reviews, hospital admissions and treatment for these complications related to IPCs. Additionally, there is a huge psychological impact of living with a home catheter that is a constant reminder of their cancer and this has been shown to affect quality of life negatively. Hence, IPCs should not be considered the \"ideal\" treatment for MPE management and clinicians should reflect the equipoise of the evidence for the benefits and accurately reflect the adverse effects of IPCs in their discussions with patients to facilitate informed decision making.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"240034"},"PeriodicalIF":2.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555583/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-12eCollection Date: 2024-10-01DOI: 10.1183/20734735.5081-2024
[This corrects the article DOI: 10.1183/20734735.0081-2024.].
[This corrects the article DOI: 10.1183/20734735.0081-2024.].
{"title":"Erratum: \"Steroids in severe community-acquired pneumonia\". S. Ananth, A.G. Mathioudakis, J. Hansel. <i>Breathe</i> 2024; 20: 240081.","authors":"","doi":"10.1183/20734735.5081-2024","DOIUrl":"https://doi.org/10.1183/20734735.5081-2024","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1183/20734735.0081-2024.].</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"245081"},"PeriodicalIF":2.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-12eCollection Date: 2024-10-01DOI: 10.1183/20734735.0044-2024
Marie Mayenga, Ana Rita Pedroso, Marion Ferreira, Thomas Gille, Maria Joana Pereira Catarata, Boris Duchemann
Advancements in immunotherapy in the perioperative setting have revolutionised the treatment of resectable nonsmall cell lung cancer (NSCLC). Here we present the methodology and results of the clinical trial CheckMate 816 demonstrating the benefit of neoadjuvant therapy with nivolumab plus chemotherapy compared with chemotherapy alone. Furthermore, this article discusses the implications for future practice in resectable NSCLC and the need for future research.
{"title":"The CheckMate 816 trial: a milestone in neoadjuvant chemoimmunotherapy of nonsmall cell lung cancer.","authors":"Marie Mayenga, Ana Rita Pedroso, Marion Ferreira, Thomas Gille, Maria Joana Pereira Catarata, Boris Duchemann","doi":"10.1183/20734735.0044-2024","DOIUrl":"https://doi.org/10.1183/20734735.0044-2024","url":null,"abstract":"<p><p>Advancements in immunotherapy in the perioperative setting have revolutionised the treatment of resectable nonsmall cell lung cancer (NSCLC). Here we present the methodology and results of the clinical trial CheckMate 816 demonstrating the benefit of neoadjuvant therapy with nivolumab plus chemotherapy compared with chemotherapy alone. Furthermore, this article discusses the implications for future practice in resectable NSCLC and the need for future research.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"240044"},"PeriodicalIF":2.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555582/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-12eCollection Date: 2024-10-01DOI: 10.1183/20734735.0229-2023
Augusta Beech, Andrew Higham, Sophie Booth, Vickram Tejwani, Frederik Trinkmann, Dave Singh
COPD is a heterogeneous condition, with tobacco smoking being the main environmental risk factor. The presence of type 2 (T2) inflammation is a well-recognised feature of asthma; however, it is now apparent that a subset of COPD patients also displays evidence of T2 inflammation with respect to elevated eosinophil counts and altered gene and protein expression of several T2 inflammatory mediators. T2 inflammatory mediators represent an attractive therapeutic target in both COPD and asthma; however, the efficacy of pharmaceutical interventions varies between diseases. Furthermore, the nature of some shared clinical features also differs. We provide a narrative review of differences in the nature of T2 inflammation between COPD and asthma, which may partly explain phenotypic differences between diseases. We focus on evidence from studies of pulmonary histopathology, sputum and epithelial gene and protein expression, and response to pharmacological interventions targeted at T2 inflammation.
{"title":"Type 2 inflammation in COPD: is it just asthma?","authors":"Augusta Beech, Andrew Higham, Sophie Booth, Vickram Tejwani, Frederik Trinkmann, Dave Singh","doi":"10.1183/20734735.0229-2023","DOIUrl":"https://doi.org/10.1183/20734735.0229-2023","url":null,"abstract":"<p><p>COPD is a heterogeneous condition, with tobacco smoking being the main environmental risk factor. The presence of type 2 (T2) inflammation is a well-recognised feature of asthma; however, it is now apparent that a subset of COPD patients also displays evidence of T2 inflammation with respect to elevated eosinophil counts and altered gene and protein expression of several T2 inflammatory mediators. T2 inflammatory mediators represent an attractive therapeutic target in both COPD and asthma; however, the efficacy of pharmaceutical interventions varies between diseases. Furthermore, the nature of some shared clinical features also differs. We provide a narrative review of differences in the nature of T2 inflammation between COPD and asthma, which may partly explain phenotypic differences between diseases. We focus on evidence from studies of pulmonary histopathology, sputum and epithelial gene and protein expression, and response to pharmacological interventions targeted at T2 inflammation.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"230229"},"PeriodicalIF":2.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-12eCollection Date: 2024-10-01DOI: 10.1183/20734735.0055-2024
Chun Ian Soo, Wai Ling Leong, Nadia Fareeda Muhammad Gowdh, Leng Cheng Sia, Vijayan Munusamy, Chee Kuan Wong, Nazarina Abdul Rahman
Mucoepidermoid carcinoma is a rare primary tumour of the lung. Diagnosis can be made after careful exclusion of other lung neoplasms, especially those with overlapping histological and radiological features. https://bit.ly/4fcISSm.
{"title":"An elderly woman with acute respiratory failure and diffuse pulmonary changes.","authors":"Chun Ian Soo, Wai Ling Leong, Nadia Fareeda Muhammad Gowdh, Leng Cheng Sia, Vijayan Munusamy, Chee Kuan Wong, Nazarina Abdul Rahman","doi":"10.1183/20734735.0055-2024","DOIUrl":"https://doi.org/10.1183/20734735.0055-2024","url":null,"abstract":"<p><p><b>Mucoepidermoid carcinoma is a rare primary tumour of the lung. Diagnosis can be made after careful exclusion of other lung neoplasms, especially those with overlapping histological and radiological features.</b> https://bit.ly/4fcISSm.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"240055"},"PeriodicalIF":2.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555587/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-12eCollection Date: 2024-10-01DOI: 10.1183/20734735.0105-2024
Clara Bianquis, Giancarlo De Leo, Giorgio Morana, Marta Duarte-Silva, Santi Nolasco, Rūdolfs Vilde, Athiwat Tripipitsiriwat, Pedro Viegas, Martins Purenkovs, Marieke Duiverman, Christian Karagiannids, Christoph Fisser
The Respiratory Intensive Care Assembly of the European Respiratory Society gathered in Berlin to organise the third Respiratory Failure and Mechanical Ventilation Conference in February 2024. The conference covered key points of acute and chronic respiratory failure in adults. During the 3-day conference ventilatory strategies, patient selection, diagnostic approaches, treatment and health-related quality of life topics were addressed by a panel of international experts. In this article, lectures delivered during the event have been summarised by early career members of the Assembly and take-home messages highlighted.
{"title":"Highlights from the Respiratory Failure and Mechanical Ventilation Conference 2024.","authors":"Clara Bianquis, Giancarlo De Leo, Giorgio Morana, Marta Duarte-Silva, Santi Nolasco, Rūdolfs Vilde, Athiwat Tripipitsiriwat, Pedro Viegas, Martins Purenkovs, Marieke Duiverman, Christian Karagiannids, Christoph Fisser","doi":"10.1183/20734735.0105-2024","DOIUrl":"https://doi.org/10.1183/20734735.0105-2024","url":null,"abstract":"<p><p>The Respiratory Intensive Care Assembly of the European Respiratory Society gathered in Berlin to organise the third Respiratory Failure and Mechanical Ventilation Conference in February 2024. The conference covered key points of acute and chronic respiratory failure in adults. During the 3-day conference ventilatory strategies, patient selection, diagnostic approaches, treatment and health-related quality of life topics were addressed by a panel of international experts. In this article, lectures delivered during the event have been summarised by early career members of the Assembly and take-home messages highlighted.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"240105"},"PeriodicalIF":2.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555592/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-12eCollection Date: 2024-10-01DOI: 10.1183/20734735.0111-2024
Katie Adams, Rahul Bhatnagar
Indwelling pleural catheters (IPCs) have rapidly grown in popularity since their introduction for the management of recurrent pleural effusions. In malignant pleural effusions especially, there has been a shift away from measuring pleurodesis success and towards more patient-centred outcomes. Multiple randomised controlled trials have shown that despite lower rates of pleurodesis, symptom control and quality of life outcomes are comparable when compared to alternatives such as talc pleurodesis. IPCs have the added benefit of minimising inpatient hospital stays and reducing the need for recurrent pleural interventions, key priorities for patients with palliative disease. As a result, IPC treatment is associated with excellent patient satisfaction coupled with acceptably low complication rates. Furthermore, in patients with a short life expectancy they confer a cost benefit for the healthcare system. Far from causing harm, IPCs are now recommended as first-line treatment by current clinical guidelines. In malignant pleural disease, guidance advocates IPCs should be offered as a first-line option with the focus on patient priorities and preferences. Ultimately IPCs provide a safe, effective, ambulatory option for managing recurrent pleural effusions.
{"title":"Con: indwelling pleural catheters cause harm to patients.","authors":"Katie Adams, Rahul Bhatnagar","doi":"10.1183/20734735.0111-2024","DOIUrl":"https://doi.org/10.1183/20734735.0111-2024","url":null,"abstract":"<p><p>Indwelling pleural catheters (IPCs) have rapidly grown in popularity since their introduction for the management of recurrent pleural effusions. In malignant pleural effusions especially, there has been a shift away from measuring pleurodesis success and towards more patient-centred outcomes. Multiple randomised controlled trials have shown that despite lower rates of pleurodesis, symptom control and quality of life outcomes are comparable when compared to alternatives such as talc pleurodesis. IPCs have the added benefit of minimising inpatient hospital stays and reducing the need for recurrent pleural interventions, key priorities for patients with palliative disease. As a result, IPC treatment is associated with excellent patient satisfaction coupled with acceptably low complication rates. Furthermore, in patients with a short life expectancy they confer a cost benefit for the healthcare system. Far from causing harm, IPCs are now recommended as first-line treatment by current clinical guidelines. In malignant pleural disease, guidance advocates IPCs should be offered as a first-line option with the focus on patient priorities and preferences. Ultimately IPCs provide a safe, effective, ambulatory option for managing recurrent pleural effusions.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"240111"},"PeriodicalIF":2.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555581/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Palliative care pertains to the holistic multidimensional concept of "patient-centred" care. It is an interprofessional specialty, primarily aiming to improve quality of care for cancer patients and their families, from the time of diagnosis of malignant disease, over the continuum of cancer care, and extending after the patient's death to the period of bereavement to support the patient's family. There are various complex and frequently unmet needs of lung cancer patients and their families/caregivers, not only physical but also psychological, social, spiritual and cultural. Systematic monitoring of patients' symptoms using validated questionnaires and patient-reported outcomes (PROs), on a regular basis, is highly encouraged and recommended in recent guidelines on the role of PRO measures in the continuum of cancer clinical care. It improves patient-physician communication, physician awareness of symptoms, symptom control, patient satisfaction, health-related quality of life and cost-effectiveness. This implies that all treating physicians should improve their skills in communication with lung cancer patients/relatives and become more familiar with this multidimensional assessment, repeatedly screening patients for palliative care needs. Therefore, they should receive education and training to develop palliative care knowledge, skills and attitudes. This review is dedicated to lung cancer palliative care essentials that should be within the competences of treating physicians, i.e. pneumologists/thoracic oncologists.
姑息关怀是 "以病人为中心 "的整体多维关怀理念。它是一门跨专业的专科,主要目的是提高癌症患者及其家属的护理质量,从诊断出恶性疾病开始,贯穿癌症护理的整个过程,并在患者去世后延伸到丧期,为患者家属提供支持。肺癌患者及其家属/照顾者有各种复杂且经常得不到满足的需求,这些需求不仅包括生理需求,还包括心理、社会、精神和文化需求。最近关于 PRO 测量在癌症临床护理中的作用的指南中,大力提倡并建议定期使用有效问卷和患者报告结果(PRO)对患者的症状进行系统监测。它能改善医患沟通、医生对症状的认识、症状控制、患者满意度、与健康相关的生活质量和成本效益。这意味着所有主治医生都应提高与肺癌患者/亲属沟通的技巧,并更加熟悉这种多维评估,反复筛查患者的姑息治疗需求。因此,他们应接受教育和培训,以培养姑息关怀的知识、技能和态度。本综述将专门讨论肺癌姑息关怀的基本要素,这些要素应属于主治医生(即肺科/胸部肿瘤科医生)的能力范围。
{"title":"Palliative care in lung cancer: tumour- and treatment-related complications in lung cancer and their management.","authors":"Dragana Jovanovic, Vesna Ceriman-Krstic, Pınar Akın Kabalak, Lucia Viola, Konstantinos Papatheodosiou","doi":"10.1183/20734735.0203-2023","DOIUrl":"https://doi.org/10.1183/20734735.0203-2023","url":null,"abstract":"<p><p>Palliative care pertains to the holistic multidimensional concept of \"patient-centred\" care. It is an interprofessional specialty, primarily aiming to improve quality of care for cancer patients and their families, from the time of diagnosis of malignant disease, over the continuum of cancer care, and extending after the patient's death to the period of bereavement to support the patient's family. There are various complex and frequently unmet needs of lung cancer patients and their families/caregivers, not only physical but also psychological, social, spiritual and cultural. Systematic monitoring of patients' symptoms using validated questionnaires and patient-reported outcomes (PROs), on a regular basis, is highly encouraged and recommended in recent guidelines on the role of PRO measures in the continuum of cancer clinical care. It improves patient-physician communication, physician awareness of symptoms, symptom control, patient satisfaction, health-related quality of life and cost-effectiveness. This implies that all treating physicians should improve their skills in communication with lung cancer patients/relatives and become more familiar with this multidimensional assessment, repeatedly screening patients for palliative care needs. Therefore, they should receive education and training to develop palliative care knowledge, skills and attitudes. This review is dedicated to lung cancer palliative care essentials that should be within the competences of treating physicians, <i>i.e.</i> pneumologists/thoracic oncologists.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"230203"},"PeriodicalIF":2.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-12eCollection Date: 2024-10-01DOI: 10.1183/20734735.0004-2024
Ivelina Pandjarova, Darlene Mercieca, Rolof G P Gijtenbeek, João Oliveira Pereira, Alberto Fantin, Nadia Castaldo, Elli Keramida, Kanwar Pannu, Assia Konsoulova, Avinash Aujayeb
Lung cancer is one of the leading causes of death worldwide. It can broadly be divided into small cell lung cancer (SCLC) and nonsmall cell lung cancer. There have been many advances over the recent years in both fields. The purpose of this review is to provide a concise summary of SCLC for the general respiratory readership.
{"title":"Small cell lung cancer and neuroendocrine tumours.","authors":"Ivelina Pandjarova, Darlene Mercieca, Rolof G P Gijtenbeek, João Oliveira Pereira, Alberto Fantin, Nadia Castaldo, Elli Keramida, Kanwar Pannu, Assia Konsoulova, Avinash Aujayeb","doi":"10.1183/20734735.0004-2024","DOIUrl":"https://doi.org/10.1183/20734735.0004-2024","url":null,"abstract":"<p><p>Lung cancer is one of the leading causes of death worldwide. It can broadly be divided into small cell lung cancer (SCLC) and nonsmall cell lung cancer. There have been many advances over the recent years in both fields. The purpose of this review is to provide a concise summary of SCLC for the general respiratory readership.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 3","pages":"240004"},"PeriodicalIF":2.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555584/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}